- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03727737
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improvement of Memory in Older Adults With TBI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent advances in both AD and TBI test non-pharmaceutical interventions that target chronic symptom improvement (e.g., non- invasive brain stimulation, exercise and cognitive training). In order to provide targeted therapies to patients who suffer from chronic sequela of TBI it is necessary to understand mechanisms of repair within the context of an aging brain. Repetitive TMS (rTMS) delivers therapeutic, noninvasive brain stimulation, is FDA-approved for treatment for major depression and currently used for treatment of pain, PTSD, anxiety, improvement of executive function in mild and moderate TBI, severe TBI, memory enhancement and dementia.
This treatment can induce neuronal long-term potentiation resulting in synaptic repair leading to improvements in memory function through hippocampal- cortical circuits and brain connectivity measured by resting state-fMRI (rs fMRI) particularly in default mode and central executive network (DMN & CEN). The study primarily proposes to assess the efficacy of rTMS to improve memory performance and to test rs-fMRI (i.e. DMN) as a potential biomarker to capture response to treatment in older patients suffering with chronic symptoms related to previous brain injuries (depression, PTSD etc). In addition, the study will assess other established biomarkers longitudinally (e.g.,hypometabolism via PET FDG, cortical oscillation via electroencephalography (EEG), Brain Derived Nerve Growth Factor (BDNF)and hippocampal volume from structural MRI) to capture patient response to treatment that may signal early dementia.
HYPOTHESES:
Primary:
Subjects with TBI who receive active rTMS treatment (rTMS_A) will: a) show significantly greater improvement from baseline in memory performance post rTMS intervention compared to subjects who received sham rTMS treatment (rTMS_S), and b) show stronger functional connectivity within and between DMN and CEN post rTMS intervention compared to patients who received sham (rTMS_S).
Secondary:
- Quality of Life (QOL): scores on QOL scale will improve with rTMS treatment in patients who receive rTMS treatment.
- Sustained Improvement: At 6-month follow-up, patients with TBI in rTMS_A group would be more likely to have sustained greater brain connectivity compared to patients in the rTMS_S group predicting better memory performance.
- Moderators of Response: The following variables may moderate memory function improvement in patients with TBI post intervention and at 6-month follow-up: Age, health condition variables (severity of symptoms at baseline, time to injury, baseline cognitive performance, TBI type,comorbidities (PTSD, sleep, depression), substance abuse, medication use, fatigue); physiological and biological variables (baseline hippocampal volume and/or microstructure, baseline connectivity in DMN & CEN, EEG resting and task-related cortical oscillations, and Brain Derived Neurotrophic Factor (BDNF) genotype.
- Mediators of Response: To assess the mechanism of rTMS in synaptic repair/regeneration, pre and post changes will be assessed in depression and PTSD measures, Plasma BDNF, FDG PET hypometabolism in precuneus/posterior cingulate area, EEG resting and task-related cortical oscillations, and connectivity of DLPFC (stimulation site & part of CEN) with other DMN.
SPECIFIC OBJECTIVES:
Primary Objective: a) To assess the efficacy of rTMS to predict improvement in memory performance pre and post rTMS intervention in older patients with TBI, and b) To assess rs-fMRI as a biomarker to detect these changes in memory performance.
Secondary Objective: To assess the mechanism of rTMS in synaptic repair/regeneration by assessment of structure & functional brain activity (PET/MRI, fMRI, & EEG), genetic, cognitive and behavioral function factors (including QOL, depression and PTSD).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maheen M Adamson, PhD
- Phone Number: 6502136307
- Email: madamson@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- VA Palo Alto Health Care System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 50-75 years, with a high school education
- History of mild or moderate TBI as defined by the DoD/VA Clinical Practice Guidelines for Definition of TBI
- Ability to obtain a Motor Threshold (MT) will be determined during the screening process
- Must be in the chronic stable phase of recovery (>6 months post injury) with residual cognitive difficulties that are affecting daily functioning (including self-reported memory or cognition problems)
- If on a psychotropic medication regimen, that regimen will be stable for at least 4 weeks prior to entry to the study and patient will be willing to remain on a stable regimen during the acute treatment phase
- Has an adequately stable condition and environment to enable attendance at scheduled clinic visits
- For female participants of child bearing potential, agrees to use one of the following acceptable methods of birth control: abstinence, oral contraceptive, Norplant, Depo-Provera, a condom with spermicide, a cervical cap with spermicide, a diaphragm with spermicide, an intrauterine device, surgical sterilization (having your tubes tied)
- Able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments
- Individuals who meet the study criteria but have impaired decision making capacity may participate provided they are able to voluntarily sign an Assent Form and have an LAR who can sign a Consent Form and accompany the participant to all study visits
Exclusion Criteria:
- Diagnosed with Dementia
- Pregnant or lactating female.
- Unable to be safely withdrawn, at least two-weeks prior to beginning treatment, from medications that substantially increase the risk of seizures
- Have a cardiac pacemaker or a cochlear implant
- Have an implanted device (deep brain stimulation) or metal in the brain (see standard MRI exclusion criteria including metal screening section in telephone screen, Appendix A)
- Have a mass lesion, cerebral infarct or other active CNS disease, including a seizure disorder
- Known current psychosis as determined by DSM-IV coding in chart (Axis I, psychotic disorder, schizophrenia) or a history of a non-mood psychotic disorder
- Diagnosis of Bipolar Affective Disorder I (as determined by chart review and intake interview), since this in conjunction with TBI increases seizure risk
- Current amnesic disorders, dementia, MOCA ≤ 16, or delirium.
- Current substance abuse (not including caffeine or nicotine) as determined by positive toxicology screen, or by history via AUDIT, within 3 months prior to screening
- Prior history of seizures
- Severe TBI or open head injury
- TBI within last 6 months
- Participation in another concurrent clinical trial
- Patients with prior exposure to rTMS (NOTE: TMS is allowed) or ECT
- Active current suicidal intent or plan. Patients at risk for suicide will be required to establish a written safety plan involving their primary psychiatrist. All patients at risk for suicide will be excluded from the study (as per FDA recommendation).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Sham
Patients with mild and moderate TBI will be assigned randomly to this arm and will not receive treatment
|
|
Active Comparator: ACTIVE
Patients with mild and moderate TBI will be assigned randomly to this arm and will receive treatment
|
RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CANTAB Paired Associates Learning (PAL)
Time Frame: 2-4 weeks
|
Test for visual memory and new learning: it is a hippocampal-mediated paired associates learning task.
This test has twenty-one outcome measures, covering the errors made by the participant, the number of trials required to locate the pattern(s) correctly, memory scores and stages completed (Administration time 10 minutes).
The main score provided is the sum of pairs reproduced over three trials (range: 0-30).
We will use the average number of trials needed to succeed on PAL task as the main outcome measure.
|
2-4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Connectivity Changes in the Brain
Time Frame: 2-4 weeks
|
Neuroimaging using PET/MRI to determine Functional Connectivity in Default Mode Network (DMN) and Central Executive Network (CEN) systems in the brain following rTMS treatment.
we will do this by doing ICA analysis for each network focused from the stimulation site.
|
2-4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life measure: Short Form of Veterans Rand 36 Item Health Survey (SF/VR-36)
Time Frame: 2-4 weeks
|
Measure of Quality of Life change following rTMS treatment.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
We will look at these standardized eight scores as outcomes measures as well as a total composite score as an outcome measure.
|
2-4 weeks
|
Sustained Improvement in primary Outcome Measure (CANTAB Paired Associates Learning (PAL)) at 6 months post-treatment
Time Frame: 6 months
|
At 6-month follow-up, the study primary outcome, CANTAB Paired Associate Learning task will be assessed again to identify changes that are sustained due to treatment at six-months.
This test has twenty-one outcome measures, covering the errors made by the participant, the number of trials required to locate the pattern(s) correctly, memory scores and stages completed (Administration time 10 minutes).
The main score provided is the sum of pairs reproduced over three trials (range: 0-30).
We will use the average number of trials needed to succeed on PAL task as the main outcome measure.
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADA0007AGG
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Injuries, Traumatic
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Hospital Sírio-LibanêsUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
Technical University of MunichFederal Ministry of Defence (Germany); Bundesministerium der VerteidigungRecruitingTraumatic Brain InjuriesFrance, Germany
-
Eunice Kennedy Shriver National Institute of Child...CompletedTraumatic Brain Injuries
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
University of Alabama at BirminghamCompletedTraumatic Brain InjuriesUnited States
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Seattle Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingConcussion, Brain | Brain Injury Traumatic MildUnited States
-
Washington University School of MedicineTerminated
Clinical Trials on Repetitive Transcranial magnetic Stimulation
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
Xuzhou Central HospitalThe Affiliated Hospital of Xuzhou Medical UniversityNot yet recruitingFunctional Magnetic Resonance Imaging | Executive Function Disorder
-
Al-Azhar UniversityCompleted
-
Guangzhou Psychiatric HospitalCompletedCognitive Impairment | Bipolar Disorder | RelapseChina
-
Fatih Sultan Mehmet Training and Research HospitalCompletedFailed Back Surgery Syndrome
-
Veterans Medical Research FoundationUnited States Department of DefenseCompletedHeadache | Gulf War SyndromeUnited States
-
MGH Institute of Health ProfessionsNational Institute on Deafness and Other Communication Disorders (NIDCD)Recruiting
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
First Affiliated Hospital of Zhejiang UniversityCompletedBipolar DisorderChina